Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17


Afatinib versus methotrexate as second-line treatment in Asian patients with recurrent or metastatic squamous cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 3): an open-label, randomised phase III trial.

Guo Y, Ahn MJ, Chan A, Wang CH, Kang JH, Kim SB, Bello M, Arora RS, Zhang Q, He X, Li P, Dechaphunkul A, Kumar V, Kamble K, Li W, Kandil A, Cohen EEW, Geng Y, Zografos E, Tang PZ.

Ann Oncol. 2019 Nov 1;30(11):1831-1839. doi: 10.1093/annonc/mdz388.


Epithelial-Mesenchymal Transition Predicts Survival in Oral Squamous Cell Carcinoma.

Wangmo C, Charoen N, Jantharapattana K, Dechaphunkul A, Thongsuksai P.

Pathol Oncol Res. 2019 Aug 31. doi: 10.1007/s12253-019-00731-z. [Epub ahead of print]


Hepatitis B screening rates and reactivation in solid organ malignancy patients undergoing chemotherapy in Southern Thailand.

Laiwatthanapaisan R, Sripongpun P, Chamroonkul N, Dechaphunkul A, Sathitruangsak C, Sakdejayont S, Kongkamol C, Piratvisuth T.

Clin Mol Hepatol. 2019 Dec;25(4):366-373. doi: 10.3350/cmh.2018.0111. Epub 2019 Jul 17.


Postprogression Outcomes for Osimertinib versus Standard-of-Care EGFR-TKI in Patients with Previously Untreated EGFR-mutated Advanced Non-Small Cell Lung Cancer.

Planchard D, Boyer MJ, Lee JS, Dechaphunkul A, Cheema PK, Takahashi T, Gray JE, Tiseo M, Ramalingam SS, Todd A, McKeown A, Rukazenkov Y, Ohe Y.

Clin Cancer Res. 2019 Apr 1;25(7):2058-2063. doi: 10.1158/1078-0432.CCR-18-3325. Epub 2019 Jan 18.


Osimertinib versus Standard of Care EGFR TKI as First-Line Treatment in Patients with EGFRm Advanced NSCLC: FLAURA Asian Subset.

Cho BC, Chewaskulyong B, Lee KH, Dechaphunkul A, Sriuranpong V, Imamura F, Nogami N, Kurata T, Okamoto I, Zhou C, Cheng Y, Cho EK, Voon PJ, Lee JS, Mann H, Saggese M, Reungwetwattana T, Ramalingam SS, Ohe Y.

J Thorac Oncol. 2019 Jan;14(1):99-106. doi: 10.1016/j.jtho.2018.09.004. Epub 2018 Sep 18.


Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.

Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, Dechaphunkul A, Imamura F, Nogami N, Kurata T, Okamoto I, Zhou C, Cho BC, Cheng Y, Cho EK, Voon PJ, Planchard D, Su WC, Gray JE, Lee SM, Hodge R, Marotti M, Rukazenkov Y, Ramalingam SS; FLAURA Investigators.

N Engl J Med. 2018 Jan 11;378(2):113-125. doi: 10.1056/NEJMoa1713137. Epub 2017 Nov 18.


Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial.

Soulières D, Faivre S, Mesía R, Remenár É, Li SH, Karpenko A, Dechaphunkul A, Ochsenreither S, Kiss LA, Lin JC, Nagarkar R, Tamás L, Kim SB, Erfán J, Alyasova A, Kasper S, Barone C, Turri S, Chakravartty A, Chol M, Aimone P, Hirawat S, Licitra L.

Lancet Oncol. 2017 Mar;18(3):323-335. doi: 10.1016/S1470-2045(17)30064-5. Epub 2017 Jan 26.


Clonal Evolutionary Analysis during HER2 Blockade in HER2-Positive Inflammatory Breast Cancer: A Phase II Open-Label Clinical Trial of Afatinib +/- Vinorelbine.

Goh G, Schmid R, Guiver K, Arpornwirat W, Chitapanarux I, Ganju V, Im SA, Kim SB, Dechaphunkul A, Maneechavakajorn J, Spector N, Yau T, Afrit M, Ahmed SB, Johnston SR, Gibson N, Uttenreuther-Fischer M, Herrero J, Swanton C.

PLoS Med. 2016 Dec 6;13(12):e1002136. doi: 10.1371/journal.pmed.1002136. eCollection 2016 Dec.


Clinical Characteristics and Treatment Outcomes of Patients with Primary Mediastinal Germ Cell Tumors: 10-Years' Experience at a Single Institution with a Bleomycin-Containing Regimen.

Dechaphunkul A, Sakdejayont S, Sathitruangsak C, Sunpaweravong P.

Oncol Res Treat. 2016;39(11):688-694. Epub 2016 Oct 20.


Phase 2 Study of Erlotinib in Combination With Linsitinib (OSI-906) or Placebo in Chemotherapy-Naive Patients With Non-Small-Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations.

Leighl NB, Rizvi NA, de Lima LG Jr, Arpornwirat W, Rudin CM, Chiappori AA, Ahn MJ, Chow LQ, Bazhenova L, Dechaphunkul A, Sunpaweravong P, Eaton K, Chen J, Medley S, Poondru S, Singh M, Steinberg J, Juergens RA, Gadgeel SM.

Clin Lung Cancer. 2017 Jan;18(1):34-42.e2. doi: 10.1016/j.cllc.2016.07.007. Epub 2016 Aug 8.


Genitourinary small-cell carcinoma: a single-institution experience.

Pervez N, El-Gehani F, Joseph K, Dechaphunkul A, Kamal M, Pertschy D, Venner P, Ghosh S, North S.

Curr Oncol. 2013 Oct;20(5):258-64. doi: 10.3747/co.20.1338.


Clinicopathologic characteristics and survival outcomes of patients with advanced esophageal, gastroesophageal junction, and gastric adenocarcinoma: a single-institution experience.

Dechaphunkul A, Mulder K, El-Gehani F, Ghosh S, Deschenes J, Spratlin J.

Curr Oncol. 2012 Dec;19(6):302-7. doi: 10.3747/co.19.1081.


Response to 5-Fluorouracil-based chemotherapy in a patient with metastatic colonic-type adenocarcinoma arising in a primary mediastinal teratoma.

Dechaphunkul A, Bigras G, Sawyer M.

Case Rep Oncol Med. 2012;2012:729278. doi: 10.1155/2012/729278. Epub 2012 Sep 23.


Prognostic significance of tissue inhibitor of metalloproteinase-1 in breast cancer.

Dechaphunkul A, Phukaoloun M, Kanjanapradit K, Graham K, Ghosh S, Santos C, Mackey JR.

Int J Breast Cancer. 2012;2012:290854. doi: 10.1155/2012/290854. Epub 2012 Sep 4.


Common presentation in an uncommon disease: case report of a patient with primary diffuse leptomeningeal melanocytosis.

Dechaphunkul A, Kayasut K, Oearsakul T, Koonlaboon K, Sunpaweravong P.

J Clin Oncol. 2011 Nov 20;29(33):e816-8. doi: 10.1200/JCO.2011.37.3175. Epub 2011 Oct 24. No abstract available.


The significance of galectin-3 immunohistochemistry, clinical characteristics and liver imaging in differentiating intrahepatic cholangiocarcinoma from adenocarcinoma liver metastasis.

Dechaphunkul A, Kanngurn S, Dechsukhum C, Tanutit P, Khow-Ean U, Sunpaweravong P.

J Med Assoc Thai. 2010 May;93(5):523-8.


Supplemental Content

Loading ...
Support Center